Join the Ozempic group to help and get support from people like you.
Ozempic News
ENDO: Guidelines Developed for Pregnancy Care in Preexisting Diabetes
FRIDAY, July 18, 2025 – In a joint clinical practice guideline issued by the Endocrine Society and European Society of Endocrinology, recommendations are presented for pregnancy care in individuals...
Diabetic Women Should Be Asked About Desire For Kids At Every Doctor's Visit, Guidelines Say
FRIDAY, July 18, 2025 — Doctors should ask diabetic women at every visit about their intention to have a child, to make sure they get the appropriate care prior to conception, new guidelines say. T...
GLP-1 Receptor Agonist Use in T2D Tied to Increased Risk for GERD, GERD Complications
THURSDAY, July 17, 2025 – For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased risk for gastroesophageal reflux disease (GERD)...
ENDO: Older Age, Female Sex Tied to Greater Muscle Loss With Semaglutide
THURSDAY, July 17, 2025 – Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and greater muscle loss is independently associated with...
Experts Recommend Healthy Lifestyle Changes Alongside GLP-1 Drug Use
WEDNESDAY, July 16, 2025 — GLP-1 weight-loss drugs like Ozempic and Zepbound are so effective it might seem that a person can lose weight without doing anything at all. But that’s a false notion, exp...
Diet, Exercise Can Help GLP-1 Patients Who Miss Doses
TUESDAY, July 15, 2025 — It can sometimes be tough to fill prescriptions for GLP-1 drugs like Wegovy and Zepbound, given the overwhelming popularity of the breakthrough weight-loss meds. But people w...
Certain Factors May Predict Weight Fluctuations After GLP-1 Receptor Agonist Treatment
TUESDAY, July 15, 2025 – For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs), according to a study...
GLP-1 Drugs Increase Risk Of Acid Reflux, GERD
TUESDAY, July 15, 2025 — Folks using GLP-1 weight loss drugs like Ozempic are more likely to suffer from severe acid reflux, a new study says. People with type 2 diabetes were more likely to suffer f...
Menopause Hormone Therapy Boosts GLP-1 Drug Effectiveness, Researchers Say
MONDAY, July 14, 2025 — Good news for women of a certain age: Hormone replacement therapy for menopause appears to boost the effectiveness of GLP-1 weight loss drugs like Wegovy and Zepbound, a new s...
Monthly Obesity Shot, MariTide, Shows Big Weight Loss in Trial
WEDNESDAY, June 25, 2025 — Alternatives to weekly injections of weight-loss drugs may on the way. A monthly dose of a new drug called MariTide helped participants in a phase 2 clinical trial shed a...
Rival GLP-1 Weight-Loss Drug, Ecnoglutide, Emerges From China
TUESDAY, June 24, 2025 — A new Chinese-developed GLP-1 weight loss drug could prove a new competitor to blockbuster drugs Ozempic/Wegovy and Zepbound, clinical trial results show. Ecnoglutide helped p...
Studies Address Muscle Loss Caused By GLP-1 Drugs, such as Ozempic and Zepbound
TUESDAY, June 24, 2025 — GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with fat. Experts are now turning their attention t...
Semaglutide Offers Cardiovascular Edge Over Empagliflozin in Type 2 Diabetes
FRIDAY, June 20, 2025 – For patients aged 45 years or older with type 2 diabetes, semaglutide seems to confer some advantage over empagliflozin in terms of mortality and cardiovascular event risks,...
Few Adolescents With Obesity Prescribed Obesity Medications
FRIDAY, June 13, 2025 – Despite an increase in the prevalence of prescribing, only 0.5 percent of U.S. adolescents with obesity were prescribed an obesity medication in 2023, according to research...
Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials
THURSDAY, June 12, 2025 – For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower than the percentages...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Chronic Kidney Disease, Cardiovascular Risk Reduction, Diabetes, Type 2